论文部分内容阅读
市场上作商品淮山药流通而药典未收载的山药(原植物为山薯(Dioscorea fordii Prain et Burk.)、褐苞薯蓣(D.persimilis Prain et Burk.)、参薯(D.alata L.)),药用历史悠久,药源丰富,已形成了较大的产区。在质量方面,与药典收载的怀山药(原植物为薯蓣(D.opposita Thunb.))比较,其有效成分和主要成分如多糖、尿囊素和氨基酸等含量都极为相似,但在多糖的单糖组成上,占优势的单糖种类不同。在药理试验中,四种山药(包括怀山药)效果都基本相同,具有增强机体能力、助消化和增强免疫功能的效果。因此,我们认为,原植物为山薯、参薯及褐苞薯蓣的淮山药作为新药源开发是可行的。
Dioscorea fordii Prain et Burk., D. persimilis Prain et Burk., And D.alata L. are grown on the market. However, )), Medicinal has a long history, rich source of medicine, has formed a larger producing areas. In terms of quality, compared with D. yunnanensis (D.opposita Thunb.) Contained in Pharmacopoeia, the active ingredients and main components such as polysaccharides, allantoin and amino acids are very similar in content, but in polysaccharides Monosaccharide composition, the dominant monosaccharide different types. In the pharmacological test, the four kinds of yam (including Chinese yam) are basically the same in effect, and have the effect of enhancing the body’s ability to help digestion and enhance the immune function. Therefore, in our opinion, it is feasible to develop the yam and yam medicines, which are original plants of potato, sweet potato and brown yam, as new drug sources.